March 15, 20160Comments

Today’s 40% Drop Is Not Enough For Valeant Pharmaceuticals

Valeant Pharmaceuticals (VRX: $36/share) had been in a bit of a limbo lately, as investors awaited the long delayed 4Q15 results. The company finally released its earnings today and the results were to be expected if you heeded our previous warnings.

by Kyle Guske II, Senior Investment Analyst, MBA

March 14, 20160Comments

Danger Zone: Traditional Corporate Consulting

Those consultants who adopt cutting-edge tools will experience more success than those that remain wedded to older, more manual techniques. It’s time we place Traditional Corporate Consulting in the Danger Zone.

by Kyle Guske II, Senior Investment Analyst, MBA

March 14, 20160Comments

“Zillow Is Risky And Vulnerable” – Barron’s

This past weekend, Barron’s magazine featured our research for the third time in 2016 and 19th time since 2014. This time, Barron’s featured research from our Danger Zone report on Zillow Group (ZG).

by Kyle Guske II, Senior Investment Analyst, MBA

March 11, 20160Comments

Danger Zone Call Featured In SumZero Face Off

SumZero featured our analysis on the multitude of issues facing Valeant Pharmaceuticals (VRX).

by Kyle Guske II, Senior Investment Analyst, MBA

March 10, 20160Comments

David Trainer Explains Why Zillow Group Is In The Danger Zone

CEO David Trainer sat down with Chuck Jaffe of Money Life and MarketWatch.com to talk about our Danger Zone pick this past week: Danger Zone: Zillow Group (ZG).

by Kyle Guske II, Senior Investment Analyst, MBA

March 7, 20160Comments

Danger Zone: Zillow Group (ZG)

This week’s Danger Zone pick, Zillow Group (ZG), sounds multiple alarms: unusually misleading non-GAAP earnings, overvalued stock, and broken business model.

by Kyle Guske II, Senior Investment Analyst, MBA

March 3, 20160Comments

David Trainer On Why Valeant Phamaceuticals Is In The Danger Zone

CEO David Trainer sat down with Chuck Jaffe of Money Life and MarketWatch.com to talk about our Danger Zone pick this past week: Danger Zone: Valeant Pharmaceuticals (VRX).

by Kyle Guske II, Senior Investment Analyst, MBA

February 29, 20164Comments

Danger Zone: Valeant Pharmaceuticals (VRX)

We’ve been highlighting the dangers of Valeant for over two years and we do not see them abating. As long as management is incentivized to destroy shareholder value, Valeant is in the Danger Zone.

by Kyle Guske II, Senior Investment Analyst, MBA

February 23, 20161Comments

Why Investors Need Independent Research

Some of the best research in the world comes from Wall Street. It has long been a leader in providing investors with ideas and strategies for investing. At the same time, it is important not to paint all Wall Street research with the same brush. Not all of Wall Street is the same, and some of the research it produces poses certain risks.

by Kyle Guske II, Senior Investment Analyst, MBA

February 19, 20160Comments

Danger Zone Performance Worth Noting

The market awards the most value to the companies that give the most back. It punishes those that do not create value. Figure 1 shows how well our Danger Zone picks have done.

by Kyle Guske II, Senior Investment Analyst, MBA

February 18, 20160Comments

David Trainer Explains Why Post Holdings Is In The Danger Zone

CEO David Trainer sat down with Chuck Jaffe of Money Life and MarketWatch.com to talk about our Danger Zone pick this past week: Danger Zone: Post Holdings (POST).

by Kyle Guske II, Senior Investment Analyst, MBA

February 15, 20162Comments

Danger Zone: Post Holdings (POST)

This week’s Danger Zone focuses on another food products business, similar to recent Danger Zone stocks WhiteWave (WWAV) and Snyder's-Lance (LNCE). Large destruction of shareholder value, skyrocketing debt levels, and insufficient returns on invested capital (ROIC) play a part in Post Holdings (POST: $67/share) landing in the Danger Zone this week.

by Kyle Guske II, Senior Investment Analyst, MBA

February 15, 20160Comments

“LinkedIn Is Still Significantly Overvalued” – Barron’s

This past weekend, Barron’s magazine featured our research for the second time in 2016 and 18th time since 2014. This time, Barron’s featured research from our Danger Zone report, and recent price update on LinkedIn (LNKD).

by Kyle Guske II, Senior Investment Analyst, MBA

February 12, 20160Comments

Price Target Update: Proofpoint (PFPT)

Due to change in market mentality, and in light of the recent downturn in the market, we felt it time to revise our price target for Proofpoint (PFPT)

by Kyle Guske II, Senior Investment Analyst, MBA

February 11, 20160Comments

Price Target Update: Twitter (TWTR)

Due to change in market mentality, and in light of the recent downturn in the market, we felt it time to revise our price target for Twitter (TWTR)

by Kyle Guske II, Senior Investment Analyst, MBA

February 11, 20160Comments

David Trainer Explains Why Pure Storage Is In The Danger Zone

CEO David Trainer sat down with Chuck Jaffe of Money Life and MarketWatch.com to talk about our Danger Zone pick this past week: Danger Zone: Pure Storage (PSTG).

by Kyle Guske II, Senior Investment Analyst, MBA

February 1, 20163Comments

Danger Zone: WhiteWave Foods Company (WWAV)

This week’s Danger Zone focuses on a company with a history of failed acquisitions that operates in a crowded market. Once the rest of the market catches on to the divergence between economic and accounting earnings, this stock is in for a big drop.

by Kyle Guske II, Senior Investment Analyst, MBA

January 28, 20160Comments

David Trainer Explains Why Suspended Ratings Are In The Danger Zone

CEO David Trainer sat down with Chuck Jaffe of Money Life and MarketWatch.com to talk about our Danger Zone pick this past week: Danger Zone: Suspended Ratings.

by Kyle Guske II, Senior Investment Analyst, MBA

January 25, 20162Comments

Danger Zone: Suspended Ratings

We suspend our ratings on certain stocks when we feel the company's latest reported financials are no longer reliable or indicative of the risk/reward of the stock. For example, an announcement of an acquisition or spin-off means the current financial statements could change significantly.

by Kyle Guske II, Senior Investment Analyst, MBA

January 21, 20160Comments

David Trainer Discusses The Danger Zone “Lowlights” From 2015

CEO David Trainer sat down with Chuck Jaffe of Money Life and MarketWatch.com to talk about our Danger Zone pick this past week: Danger Zone Lowlights 2015.

by Kyle Guske II, Senior Investment Analyst, MBA

« Older Articles Newer Articles »